ADC Therapeutics' ZYNLONTA Achieves 94% Response Rate in Lymphoma Trial
Lausanne, Wednesday, 11 December 2024.
The LOTIS-7 trial shows ZYNLONTA’s combination with glofitamab achieves a 94% overall response rate in relapsed or refractory diffuse large B-cell lymphoma, presenting promising treatment potential.
Breakthrough Results in Clinical Trial
ADC Therapeutics SA (NYSE: ADCT) has announced groundbreaking results from their LOTIS-7 Phase 1b clinical trial as of November 20, 2024 [1][2]. The trial evaluated ZYNLONTA® in combination with the bispecific antibody glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Among 18 evaluable patients, the combination therapy achieved an impressive 94% overall response rate (ORR) and a 72% complete response (CR) rate [1][2].
Exceptional Response at Higher Dosage
The study revealed particularly promising results at the 150 µg/kg dose level of ZYNLONTA, which is the currently approved dose for monotherapy in third-line DLBCL patients. At this dosage, the treatment achieved a perfect 100% overall response rate, with 78% of patients achieving complete response [1]. Notably, 12 out of 13 patients who achieved complete response maintained their status through the cutoff date [1], demonstrating the treatment’s durability.
Safety Profile and Treatment Tolerance
The safety analysis, conducted across all 29 trial participants, indicates that the ZYNLONTA-glofitamab combination is generally well-tolerated [1]. The most common Grade 3 or higher treatment emergent adverse events included neutropenia (24%), lymphopenia (7%), and hypokalemia (7%) [1]. Cytokine Release Syndrome was observed in 34.5% of patients but remained at Grade 1 or 2 and was manageable with standard treatment [1].
Future Outlook and Development Plans
ADC Therapeutics is maintaining a strong financial position with a cash runway extending into mid-2026 [2]. The company plans to complete enrollment of the dose expansion phase in the first half of 2025 [2]. According to Chief Executive Officer Ameet Mallik, these compelling initial results support the potential of ZYNLONTA plus glofitamab to become a best-in-class combination therapy [2], potentially transforming the treatment landscape for DLBCL patients.